Changes In Endothelial Cell Counts In Patients After Preserflo Microshunt Implantation In 3 Months Follow-Up.

Published 2022 - 40th Congress of the ESCRS

Reference: PP18.04 | Type: ESCRS 2022 - Posters | DOI: 10.82333/z38j-qs22

Authors: Anna Mikolajczyk* ¹ , Michal Bogocz ¹ , Wojciech Maruszczyk ¹ , Mariola Dorecka ² , Ewa Mrukwa-Kominek ³

¹Department of Ophthalmology,Prof. Kornel Gibinski University Clinical Centre, Katowice, Poland,Katowice,Poland, ²Department of Ophthalmology,Faculty of Medical Sciences Medical University of Silesia,Katowice,Poland;Department of Ophthalmology,Prof. Kornel Gibinski University Clinical Centre, Katowice, Poland,Katowice,Poland, ³Department of Ophthalmology,Prof. Kornel Gibinski University Clinical Centre, Katowice, Poland,Katowice,Poland;Department of Ophthalmology,Faculty of Medical Sciences Medical University of Silesia,Katowice,Poland

Purpose

Preserflo MicroShunt is a minimally-invasive glaucoma drainage micro-tube used to shunt aqueous humor from the anterior chamber to the subtenon space. It is a common filtering surgery for patients with open-angle glaucoma and medically uncontrollable intraocular pressure (IOP). The aim of the study is to analyze the effects of Preserflo Microshunt implantation on the corneal endothelial cell density.

Setting

Department of Ophthalmology, Professor K. Gibinski's University Clinical Centre. Medical University of Silesia in Katowice, Poland.

Methods

The study included 11 patients qualified for antiglaucoma procedure the Preserflo Microshunt implantation due to poorly controlled IOP on acceptable maximal medication.

Patient was examined 1, 2, 4, 8, 12 weeks after surgery.

On each visit standard ophthalmic examination was performed, which included BCVA, Goldmann Applanation Tonometry, Anterior Segment OCT, Specular Microscopy to assess endothelial cells counts.

The corneal endothelial cell density was examined before and 3 months post surgery.

Results

Vision acquity remained stable, although the slight deterioration of VA during the first 1-2 weeks were observed, which resolved after 2-3 weeks after surgery.

The implant position assessed in AS-OCT was stable during the observation period and no significant implant contact with the cornea was observed.

There is no significant changes in ECC before and after surgery. MV 2308 cells/mm2 and 2273 cells /mm2 respectively before and after surgery.

Transient hypotony with subsequent serous choroidal detachment was observed in one patient which resolved on medical therapy. No surgical intervention was needed.

No sight threatening complications were observed during the observation period such as endophthalmitis, serous hypotony, hemorrhage.

Conclusions

The procedure is considered to be of high safety profile. Preserflo implantation can lead to some endothelial changes although there is not enogh data to conclude that preserflo implantation can lead to endothelial cells loss.

In some particular patients the endothelial cell change is bigger than in the whole group and it has to be further examined. A long-term prospective study with pre and postoperative endothelial cell count and AS-OCT evaluation of the device positioning would be of great interest to assess the real impact of ECL on a bigger cohort of patients.